Krystal Biotech (KRYS) Change in Accured Expenses (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Change in Accured Expenses data on file, last reported at -$6.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses fell 270.83% year-over-year to -$6.3 million; the trailing twelve-month figure through Mar 2026 stood at $4.1 million (down 71.25% YoY), and the FY2025 full-year result was $14.1 million, up 161.62% from the prior year.
• Change in Accured Expenses eased to -$6.3 million in Q1 2026, from $5.8 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.5 million in Q4 2024 to a low of -$6.3 million in Q1 2026.
• A 5-year average of $1.3 million and a median of $1.9 million in 2024 frame the typical range for Change in Accured Expenses.
• Across the five-year window, Change in Accured Expenses soared 629.35% in 2022 and tumbled 272.03% in 2023, its largest moves.
• Tracing KRYS's Change in Accured Expenses over 5 years: stood at $2.2 million in 2022, then surged by 70.75% to $3.7 million in 2023, then jumped by 103.18% to $7.5 million in 2024, then fell by 22.68% to $5.8 million in 2025, then slumped by 209.09% to -$6.3 million in 2026.
• Business Quant data shows KRYS's Change in Accured Expenses at -$6.3 million in Q1 2026, $5.8 million in Q4 2025, and $5.9 million in Q3 2025.